Low Vitamin B12 and Its Impact on RLS/PLMs
While emerging evidence suggests an association between low vitamin B12 levels and restless legs syndrome, the 2025 AASM clinical practice guideline does not include vitamin B12 screening or supplementation in its treatment recommendations, focusing instead on iron status as the primary nutritional intervention. 1
Current Guideline Position
The most recent and authoritative 2025 AASM guideline for RLS and PLMD treatment makes no recommendations regarding vitamin B12 assessment or supplementation 1. The guideline emphasizes:
- Iron repletion as the primary nutritional intervention (strong recommendation for IV ferric carboxymaltose, conditional for ferrous sulfate) 1
- Vitamin C supplementation only in end-stage renal disease patients with RLS 1
- No mention of B12, folate, or other B vitamins in the treatment algorithm
This represents a significant gap between emerging research and current clinical practice standards.
Research Evidence on B12 and RLS
Recent Findings
The most recent 2026 cross-sectional study in adolescents found significantly lower vitamin B12 levels in RLS patients compared to controls, with higher RLS prevalence in the B12-deficient group 2. However, this study's cross-sectional design prevents establishing causality.
A 2025 meta-analysis demonstrated:
- No significant B12 deficiency in general RLS populations (P = 0.59) 3
- Low folate associated with RLS only in pregnant women (P = 0.007), not in non-pregnant patients 3
- Vitamin D deficiency more consistently linked to RLS than B12 3
Conflicting Data
A 2022 case-control study found:
- Significantly reduced B12 levels in RLS patients 4
- Negative correlation between B12 levels and symptom severity (IRLS scores) 4
- B12 independently associated with RLS development (OR = 0.97) 4
However, a 2008 study of 228 subjects found no significant differences in B12 levels between RLS patients and controls, and no association with levodopa treatment 5.
Clinical Implications
What This Means for Practice
Given the absence of guideline support and conflicting research evidence, routine B12 screening specifically for RLS cannot be recommended as standard practice. However:
Check B12 in specific contexts:
Prioritize iron status first:
If B12 deficiency is documented:
- Treat the deficiency for its own sake (neurologic, hematologic indications)
- RLS symptom improvement may occur but is not guaranteed based on current evidence
- No RCTs exist demonstrating B12 supplementation efficacy for RLS 3
Common Pitfalls
- Do not delay evidence-based RLS treatment (gabapentin, pregabalin, IV iron) while pursuing B12 supplementation trials 1
- Avoid attributing RLS solely to B12 deficiency without considering iron status, medications, and other secondary causes 7
- Do not confuse association with causation – the cross-sectional studies cannot prove B12 deficiency causes RLS 2, 4
Regarding PLMs Specifically
No research evidence addresses vitamin B12's impact on periodic limb movements specifically. The 2025 AASM guideline provides minimal treatment recommendations for PLMD, suggesting against valproic acid and triazolam only 1. PLMs commonly accompany RLS but most individuals with PLMs do not have RLS 7.
Bottom Line Algorithm
- All RLS patients: Check ferritin and transferrin saturation
- Selective B12 screening: Only in patients with risk factors for deficiency or atypical features
- If B12 deficient: Treat the deficiency but initiate guideline-concordant RLS therapy simultaneously
- First-line RLS treatment: Gabapentin, pregabalin, or IV iron (if appropriate iron parameters) 1
The evidence for B12's role in RLS pathophysiology remains preliminary and inconsistent, insufficient to warrant routine screening or supplementation as RLS-specific interventions.